Valuation: MaaT Pharma

Market Cap 18.66M 21.02M 17.46M 15.82M 29.88M 2.03B 30.1M 210M 81.55M 1.03B 78.88M 77.19M 3.32B P/E 2026 *
-0.52x
P/E 2027 * -0.89x
Enterprise Value 32.46M 36.57M 30.38M 27.53M 52M 3.52B 52.37M 365M 142M 1.8B 137M 134M 5.78B EV / Sales 2026 *
3.33x
EV / Sales 2027 * 1.78x
Free-Float
36.81%
Yield 2026 *
-
Yield 2027 * -
1 day+5.43%
1 week-13.16%
Current month-8.67%
1 month-66.33%
3 months-65.62%
6 months-82.69%
Current year-79.42%
1 week 0.92
Extreme 0.916
1.19
1 month 0.92
Extreme 0.916
2.96
Current year 0.92
Extreme 0.916
8.62
1 year 0.92
Extreme 0.916
8.62
3 years 0.92
Extreme 0.916
9.96
5 years 0.92
Extreme 0.916
14.4
10 years 0.92
Extreme 0.916
14.4
Manager TitleAgeSince
Chief Executive Officer - 2013-12-31
Director of Finance/CFO 59 2024-10-31
Chief Tech/Sci/R&D Officer - 2024-06-23
Director TitleAgeSince
Director/Board Member - 2013-12-31
Director/Board Member 57 2013-12-31
Chairman - 2015-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
5/28/26 Buy

Founder

2,000 0.0106%
1/29/26
Seventure Partners SA
SellCompany 25,423 0.1356%
1/28/26
Seventure Partners SA
SellCompany 57,964 0.3091%
Change 5-day change 1-year change 3-year change Capi.($)
+5.43%-13.16%-78.00%-84.03% 19.83M
+4.16%+4.16%+49.37%+94.17% 74.31B
+2.76%-1.16%+23.05%+83.03% 56.95B
+0.24%-1.37%+4.08%+37.22% 48.3B
-3.76%-2.25%+329.09%+698.20% 44.51B
-2.30%-3.35%+26.81%+30.88% 43.8B
+0.31%-0.68%+5.30%+108.64% 41.12B
-0.11%+2.30%+9.19%+58.68% 31.07B
+4.51%+8.43%+37.27%+34.97% 28.97B
-1.96%-2.88%-8.97%-13.92% 24.53B
Average +0.93%-1.94%+39.72%+104.78% 39.36B
Weighted average by Cap. +0.77%-0.94%+56.82%+134.45%

Financials

2026 *2027 *
Net sales 9.75M 10.98M 9.12M 8.27M 15.62M 1.06B 15.73M 110M 42.62M 540M 41.23M 40.35M 1.74B 28.88M 32.53M 27.02M 24.49M 46.26M 3.14B 46.59M 325M 126M 1.6B 122M 119M 5.14B
Net income -31.69M -35.7M -29.66M -26.88M -50.77M -3.44B -51.14M -356M -139M -1.76B -134M -131M -5.64B -15.31M -17.25M -14.33M -12.99M -24.53M -1.66B -24.7M -172M -66.93M -848M -64.74M -63.35M -2.73B
Net Debt 13.8M 15.55M 12.92M 11.71M 22.11M 1.5B 22.27M 155M 60.35M 765M 58.37M 57.12M 2.46B 32.85M 37M 30.74M 27.86M 52.62M 3.57B 53M 369M 144M 1.82B 139M 136M 5.85B
Projected Income Statement - Annual - MaaT Pharma
Logo MaaT Pharma
MaaT Pharma is a late-stage biotechnology company and a leader in the development of intestinal microbiota-based drugs designed to modulate the immune system of cancer patients and improve their survival. A pioneer in its field, MaaT Pharma is developing the first immunomodulatory drug candidate based on intestinal microbiota in oncology, currently in phase 3 clinical evaluation. Thanks to its proprietary pooling (combining donations of healthy microbiota) and microbial co-culture technologies, MaaT Pharma is developing standardised drugs with high bacterial diversity, aimed at improving the survival of cancer patients.
Employees
56
Date Price Change Volume
26-10-06 €0.9900 +5.43% 69,515
26-10-05 €0.9390 -7.03% 195,649
26-10-02 €1.010 -1.94% 154,897
26-10-01 €1.030 -4.98% 112,846
26-09-30 €1.084 -4.07% 92,618
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - MaaT Pharma
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.9900EUR
Average target price
6.500EUR
Spread / Average Target
+556.57%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - MaaT Pharma
  1. Stock Market
  2. Stocks
  3. MAAT Stock